Ablynx and Merck Serono enters into second agreement to co-discover and co-develop Nanobodies

12-Oct-2010 - Belgium

Ablynx and Merck Serono, a division of Merck KGaA, announced that they have expanded their relationship and entered into a second agreement, to co-discover and co-develop Nanobodies against an inflammatory disease target.

Ablynx's Nanobodies are a class of antibody-derived therapeutic proteins that combine the advantages of conventional antibodies with key properties of small molecule drugs such as high affinity, small size allowing alternative delivery and enhanced tissue penetration and high stability.

In September 2008, Merck Serono and Ablynx entered into an agreement to co-discover and co-develop Nanobodies against two targets in oncology and immunology. This second agreement focuses on the discovery and development of Nanobody-based therapeutics against an inflammatory disease target. This new collaboration structure allows Ablynx to drive the process up to the clinic, leveraging its strengths in Nanobody discovery and preclinical development.

Under the terms of the agreement, Ablynx will receive an up-front payment of €10 million and be responsible for all activities and costs, excluding manufacturing costs, up to the delivery of a preclinical package that will form the basis for the filing of an IND or IND equivalent. Upon acceptance of the package by Merck Serono, Ablynx will be eligible for a €15 million milestone payment. Ablynx has the option to continue with Merck Serono up to a 50:50 co-development basis and share the resulting profits, or to convert this collaboration into an exclusive, worldwide licensing deal with milestone payments and significant tiered royalties. Further details of the agreement are undisclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous